Effects of BCc1 nanoparticle and its mixture with doxorubicin on survival of murine 4T1 tumor model

References

• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.2139528248415
   PubMed Web of Science ®Google Scholar
• Gupta SK, Garg A, Bar C, et al. Quaking inhibits doxorubicin-mediated cardiotoxicity through regulation of cardiac circular RNA expression. Circ Res. 2018;122(2):246–254. doi:10.1161/CIRCRESAHA.117.31133529133306
   PubMed Web of Science ®Google Scholar
• Liu Y, Jia Q, Guo Q, Wei W, Zhou J. Simultaneously activating highly selective ratiometric MRI and synergistic therapy in response to intratumoral oxidability and acidity. Biomaterials. 2018;180:104–116. doi:10.1016/j.biomaterials.2018.07.02530032045
   PubMed Web of Science ®Google Scholar
• Zhu X, Li J, Qiu X, Liu Y, Feng W, Li F. Upconversion nanocomposite for programming combination cancer therapy by precise control of microscopic temperature. Nat Commun. 2018;9(1):2176. doi:10.1038/s41467-018-04571-429872036
   PubMedGoogle Scholar
• Yuxin Liu QG, Zhu X, Feng W, et al. Optimization of prussian blue coated NaDyF4: x%LuNanocomposites for multifunctional imaging‐guided photothermal therapy. Adv Funct. 2016;26,:5120. doi:10.1002/adfm.201601478
   Web of Science ®Google Scholar
• Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy - strategies and perspectives. J Control Release. 2016;240:489–503. doi:10.1016/j.jconrel.2016.06.01227287891
   PubMed Web of Science ®Google Scholar
• Johnson-Arbor K, Dubey R. Doxorubicin In: StatPearls. Treasure Island, FL; 2018 Available from https://www.ncbi.nlm.nih.gov/books/NBK459232/. Last accessed 31 May 2019.
   Google Scholar
• Xu YC, Liu X, Li M, et al. A novel mechanism of doxorubicin resistance and tumorigenesis mediated by MicroRNA-501-5p-suppressed BLID. Mol Ther Nucleic Acids. 2018;12:578–590. doi:10.1016/j.omtn.2018.06.01130195794
   PubMedGoogle Scholar
• Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull. 2013;36(5):715–718. doi:10.1248/bpb.b12-0110223649331
   PubMed Web of Science ®Google Scholar
• Abd El-Moneim OM, Abd El-Rahim AH, Hafiz NA. Evaluation of selenium nanoparticles and doxorubicin effect against hepatocellular carcinoma rat model cytogenetic toxicity and DNA damage. Toxicol Rep. 2018;5:771–776. doi:10.1016/j.toxrep.2018.07.00330094191
   PubMed Web of Science ®Google Scholar
• Li S, Yuan S, Zhao Q, Wang B, Wang X, Li K. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. Biomed Pharmacother. 2018;100:441–447. doi:10.1016/j.biopha.2018.02.05529475141
   PubMed Web of Science ®Google Scholar
• Available from: https://www.rxlist.com/consumer_doxorubicin_adriamycin/drugs-condition.htm.
   Google Scholar
• Grigorian A, O‘Brien CB. Hepatotoxicity secondary to chemotherapy. J Clin Transl Hepatol. 2014;2(2):95–102. doi:10.14218/JCTH.2014.0001126357620
   PubMedGoogle Scholar
• Balsari A, Menard S, Colnaghi MI, Ghione M. Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin. Int J Cancer. 1991;47(6):889–892.2010231
   PubMed Web of Science ®Google Scholar
• Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38. doi:10.1016/j.addr.2016.04.02527137110
   PubMed Web of Science ®Google Scholar
• Zhao CY, Cheng R, Yang Z, Tian ZM. Nanotechnology for cancer therapy based on chemotherapy. Molecules. 2018;23:4.
   Web of Science ®Google Scholar
• Sharma M, Pandey C, Sharma N, Kamal MA, Sayeed U, Akhtar S. Cancer nanotechnology - an excursion on drug delivery systems. Anticancer Agents Med Chem. 2018;18(15):2078–2092.30033877
   PubMed Web of Science ®Google Scholar
• Nazaran MH. Chelate compounds. Google Patents US8288587B2. 2012.
   Google Scholar
• Fakharzadeh S, Sahraian MA, Hafizi M, et al. The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice. Int J Nanomedicine. 2014;9:3841–3853. doi:10.2147/IJN.S6463025143732
   PubMed Web of Science ®Google Scholar
• Maghsoudi A, Fakharzadeh S, Hafizi M, et al. Neuroprotective effects of three different sizes nanochelating based nano complexes in MPP(+) induced neurotoxicity. Apoptosis. 2015;20(3):298–309. doi:10.1007/s10495-014-1069-x25451011
   PubMed Web of Science ®Google Scholar
• Hafizi M, Hajarizadeh A, Atashi A, et al. Nanochelating based nanocomplex, GFc7, improves quality and quantity of human mesenchymal stem cells during in vitro expansion. Stem Cell Res Ther. 2015;6:226. doi:10.1186/s13287-015-0216-926597909
   PubMed Web of Science ®Google Scholar
• Kalanaky S, Hafizi M, Fakharzadeh S, et al. BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo. Drug Des Devel Ther. 2016;10:59–70. doi:10.2147/DDDT.S89694
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Principles of tumor suppression. Cell. 2004;116(2):235–246.14744434
   PubMed Web of Science ®Google Scholar
• Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle. 2007;6(9):1006–1010. doi:10.4161/cc.6.9.421117457049
   PubMed Web of Science ®Google Scholar
• Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995;55(22):5187–5190.7585571
   PubMed Web of Science ®Google Scholar
• Romanov VS, Rudolph KL P21 shapes cancer evolution. Nat Cell Biol. 2016;18(7):722–724. doi:10.1038/ncb338227350444
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–823. doi:10.1073/pnas.68.4.8205279523
   PubMed Web of Science ®Google Scholar
• Mischiati C, Puviani AC, Brogli M, et al. Modulation of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) gene expression in isolated porcine hepatocytes perfused within a radial-flow bioreactor after low-temperature storing. Int J Artif Organs. 2003;26(2):139–148.12653348
   PubMed Web of Science ®Google Scholar
• Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2005;37(11):719–727.16270150
   PubMed Web of Science ®Google Scholar
• Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004;6(4):R275–83. doi:10.1186/bcr78715217493
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Wang L, Agyin J, et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One. 2010;5(4):e10365. doi:10.1371/journal.pone.001036520442777
   PubMed Web of Science ®Google Scholar
• Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res. 2005;11(5):1918–1927. doi:10.1158/1078-0432.CCR-04-197615756018
   PubMed Web of Science ®Google Scholar
• Gharibi B, Hughes FJ. Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. Stem Cells Transl Med. 2012;1(11):771–782. doi:10.5966/sctm.2010-003123197689
   PubMed Web of Science ®Google Scholar
• Hafizi M, Bakhshandeh B, Soleimani M, Atashi A. Exploring the enkephalinergic differentiation potential in adult stem cells for cell therapy and drug screening implications. In Vitro Cell Dev Biol Anim. 2012;48(9):562–569. doi:10.1007/s11626-012-9546-423054438
   PubMed Web of Science ®Google Scholar
• Hejazi E, Nasrollahzadeh J, Fatemi R, et al. Effects of combined soy isoflavone extract and docetaxel treatment on murine 4T1 breast tumor model. Avicenna J Med Biotechnol. 2015;7(1):16–21.25926948
   PubMedGoogle Scholar
• Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5–S16.15508102
   PubMed Web of Science ®Google Scholar
• Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther. 2008;324(1):160–169. doi:10.1124/jpet.107.12577317928571
   PubMed Web of Science ®Google Scholar
• Mayhew EG, Goldrosen MH, Vaage J, Rustum YM. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst. 1987;78(4):707–713.3470546
   PubMedGoogle Scholar
• Lamkanfi M, Kanneganti TD. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 2010;42(1):21–24. doi:10.1016/j.biocel.2009.09.01319782763
   PubMed Web of Science ®Google Scholar
• Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017;6(1):44. doi:10.1186/s40169-017-0175-029230567
   PubMed Web of Science ®Google Scholar
• Tian J, Min Y, Rodgers Z, et al. Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. Nanomedicine. 2017;13(3):1301–1307. doi:10.1016/j.nano.2016.11.00727884641
   PubMed Web of Science ®Google Scholar